Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced the closing of its underwritten public offering of 1,600,000 shares at a price of $47.00 per share, generating approximately $75.2 million in gross proceeds. The offering was facilitated by Piper Sandler and Stifel as joint book-running managers, with additional support from other firms. The shares were offered under a shelf registration statement effective since March 27, 2020. A final prospectus supplement has been filed with the SEC and is available on their website.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced a public offering of its common stock on June 17, 2020. The offering aims to finance implant and instrument sets for customers, fund research and development, and expand marketing efforts. The underwriters have a 30-day option to purchase additional shares. The offering is contingent on market conditions and is conducted under a registered shelf statement effective since March 27, 2020. Piper Sandler and Stifel are the joint book-running managers. No assurances are provided regarding the offering's completion or terms.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched the ApiFix Minimally Invasive Deformity Correction system in the U.S., targeting progressive adolescent idiopathic scoliosis (AIS). This posterior dynamic correction system is designed for Lenke type 1 and 5 curves, offering a less invasive alternative to spinal fusion. The device's recovery time is significantly reduced, and it allows for gradual post-operative correction. Supported by strong patent protection, ApiFix was acquired in April 2020 and aims to address treatment gaps for children with scoliosis.
OrthoPediatrics Corp. (KIDS) reported first-quarter 2020 revenues of $16.4 million, up 11.6% from $14.7 million in Q1 2019. Domestic revenue rose 30.4% to $13.4 million, while international revenue fell 32.3% to $3.0 million. The company acquired ApiFix and launched new products, expanding its portfolio. However, it suspended its full-year 2020 revenue guidance due to COVID-19 uncertainties. Operating loss increased to ($4.5 million), and net loss attributable to common stockholders was ($4.9 million), or ($0.30) per share.